Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia

Carolina Simioni, Simona Ultimo, Alberto M. Martelli, Giorgio Zauli, Daniela Milani, James A. McCubrey, Silvano Capitani, Luca M. Neri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) accounts for 25-30% of adult ALL and its incidence increases with age in adults >40 years old. Irrespective of age, the ABL1 fusion genes are markers of poor prognosis and amplification of the NUP214-ABL1 oncogene can be detected mainly in patients with T-ALL. T cell malignancies harboring the ABL1 fusion genes are sensitive to many cytotoxic agents, but up to date complete remissions have not been achieved. The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis. We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation. Cells were sensitive to anti BCR-ABL1 TKIs Imatinib, Nilotinib and GZD824, that specifically targeted the ABL1 fusion protein, but not the PI3K/Akt/mTOR axis. Four drugs against the PI3K/Akt/mTOR cascade, GSK690693, NVP-BGT226, ZSTK474 and Torin-2, showed marked cytotoxic effects on T-leukemic cells, without affecting the NUP214-ABL1 kinase and related pathway. Dephosphorylation of pAkt and pS6 showed the cytotoxicity of these compounds. Either single or combined administration of drugs against the different targets displayed inhibition of cellular viability associated with a concentration-dependent induction of apoptosis, cell cycle arrest in G0/G1 phase and autophagy, having the combined treatments a significant synergistic cytotoxic effect. Co-targeting NUP214-ABL1 fusion gene and PI3K/Akt/mTOR signaling pathway could represent a new and effective pharmacological strategy to improve the outcome in NUP214-ABL1 positive T-ALL.

Original languageEnglish
Pages (from-to)79842-79853
Number of pages12
JournalOncotarget
Volume7
Issue number48
DOIs
Publication statusPublished - 2016

Fingerprint

Phosphatidylinositol 3-Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Gene Fusion
Protein-Tyrosine Kinases
Philadelphia Chromosome
Cell Cycle Resting Phase
Cytotoxins
Autophagy
G1 Phase
Cell Cycle Checkpoints
Oncogenes
Pharmaceutical Preparations
human NUP214-ABL1 fusion protein
Leukemia
Phosphotransferases
Pharmacology
Apoptosis
T-Lymphocytes
Cell Line
Incidence

Keywords

  • Autophagy
  • NUP214-ABL1
  • PI3K/Akt/mTOR signaling
  • T-Acute Lymphoblastic Leukemia
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology

Cite this

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. / Simioni, Carolina; Ultimo, Simona; Martelli, Alberto M.; Zauli, Giorgio; Milani, Daniela; McCubrey, James A.; Capitani, Silvano; Neri, Luca M.

In: Oncotarget, Vol. 7, No. 48, 2016, p. 79842-79853.

Research output: Contribution to journalArticle

Simioni, C, Ultimo, S, Martelli, AM, Zauli, G, Milani, D, McCubrey, JA, Capitani, S & Neri, LM 2016, 'Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia', Oncotarget, vol. 7, no. 48, pp. 79842-79853. https://doi.org/10.18632/oncotarget.13035
Simioni, Carolina ; Ultimo, Simona ; Martelli, Alberto M. ; Zauli, Giorgio ; Milani, Daniela ; McCubrey, James A. ; Capitani, Silvano ; Neri, Luca M. / Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. In: Oncotarget. 2016 ; Vol. 7, No. 48. pp. 79842-79853.
@article{969b15fc1d214970b0fee58e8e450019,
title = "Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia",
abstract = "Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) accounts for 25-30{\%} of adult ALL and its incidence increases with age in adults >40 years old. Irrespective of age, the ABL1 fusion genes are markers of poor prognosis and amplification of the NUP214-ABL1 oncogene can be detected mainly in patients with T-ALL. T cell malignancies harboring the ABL1 fusion genes are sensitive to many cytotoxic agents, but up to date complete remissions have not been achieved. The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis. We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation. Cells were sensitive to anti BCR-ABL1 TKIs Imatinib, Nilotinib and GZD824, that specifically targeted the ABL1 fusion protein, but not the PI3K/Akt/mTOR axis. Four drugs against the PI3K/Akt/mTOR cascade, GSK690693, NVP-BGT226, ZSTK474 and Torin-2, showed marked cytotoxic effects on T-leukemic cells, without affecting the NUP214-ABL1 kinase and related pathway. Dephosphorylation of pAkt and pS6 showed the cytotoxicity of these compounds. Either single or combined administration of drugs against the different targets displayed inhibition of cellular viability associated with a concentration-dependent induction of apoptosis, cell cycle arrest in G0/G1 phase and autophagy, having the combined treatments a significant synergistic cytotoxic effect. Co-targeting NUP214-ABL1 fusion gene and PI3K/Akt/mTOR signaling pathway could represent a new and effective pharmacological strategy to improve the outcome in NUP214-ABL1 positive T-ALL.",
keywords = "Autophagy, NUP214-ABL1, PI3K/Akt/mTOR signaling, T-Acute Lymphoblastic Leukemia, Targeted therapies",
author = "Carolina Simioni and Simona Ultimo and Martelli, {Alberto M.} and Giorgio Zauli and Daniela Milani and McCubrey, {James A.} and Silvano Capitani and Neri, {Luca M.}",
year = "2016",
doi = "10.18632/oncotarget.13035",
language = "English",
volume = "7",
pages = "79842--79853",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "48",

}

TY - JOUR

T1 - Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia

AU - Simioni, Carolina

AU - Ultimo, Simona

AU - Martelli, Alberto M.

AU - Zauli, Giorgio

AU - Milani, Daniela

AU - McCubrey, James A.

AU - Capitani, Silvano

AU - Neri, Luca M.

PY - 2016

Y1 - 2016

N2 - Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) accounts for 25-30% of adult ALL and its incidence increases with age in adults >40 years old. Irrespective of age, the ABL1 fusion genes are markers of poor prognosis and amplification of the NUP214-ABL1 oncogene can be detected mainly in patients with T-ALL. T cell malignancies harboring the ABL1 fusion genes are sensitive to many cytotoxic agents, but up to date complete remissions have not been achieved. The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis. We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation. Cells were sensitive to anti BCR-ABL1 TKIs Imatinib, Nilotinib and GZD824, that specifically targeted the ABL1 fusion protein, but not the PI3K/Akt/mTOR axis. Four drugs against the PI3K/Akt/mTOR cascade, GSK690693, NVP-BGT226, ZSTK474 and Torin-2, showed marked cytotoxic effects on T-leukemic cells, without affecting the NUP214-ABL1 kinase and related pathway. Dephosphorylation of pAkt and pS6 showed the cytotoxicity of these compounds. Either single or combined administration of drugs against the different targets displayed inhibition of cellular viability associated with a concentration-dependent induction of apoptosis, cell cycle arrest in G0/G1 phase and autophagy, having the combined treatments a significant synergistic cytotoxic effect. Co-targeting NUP214-ABL1 fusion gene and PI3K/Akt/mTOR signaling pathway could represent a new and effective pharmacological strategy to improve the outcome in NUP214-ABL1 positive T-ALL.

AB - Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) accounts for 25-30% of adult ALL and its incidence increases with age in adults >40 years old. Irrespective of age, the ABL1 fusion genes are markers of poor prognosis and amplification of the NUP214-ABL1 oncogene can be detected mainly in patients with T-ALL. T cell malignancies harboring the ABL1 fusion genes are sensitive to many cytotoxic agents, but up to date complete remissions have not been achieved. The PI3K/Akt/mTOR signaling pathway is often activated in leukemias and plays a crucial role in leukemogenesis. We analyzed the effects of three BCR-ABL1 tyrosine kinase inhibitors (TKIs), alone and in combination with a panel of selective PI3K/Akt/mTOR inhibitors, on three NUP214-ABL1 positive T-ALL cell lines that also displayed PI3K/Akt/mTOR activation. Cells were sensitive to anti BCR-ABL1 TKIs Imatinib, Nilotinib and GZD824, that specifically targeted the ABL1 fusion protein, but not the PI3K/Akt/mTOR axis. Four drugs against the PI3K/Akt/mTOR cascade, GSK690693, NVP-BGT226, ZSTK474 and Torin-2, showed marked cytotoxic effects on T-leukemic cells, without affecting the NUP214-ABL1 kinase and related pathway. Dephosphorylation of pAkt and pS6 showed the cytotoxicity of these compounds. Either single or combined administration of drugs against the different targets displayed inhibition of cellular viability associated with a concentration-dependent induction of apoptosis, cell cycle arrest in G0/G1 phase and autophagy, having the combined treatments a significant synergistic cytotoxic effect. Co-targeting NUP214-ABL1 fusion gene and PI3K/Akt/mTOR signaling pathway could represent a new and effective pharmacological strategy to improve the outcome in NUP214-ABL1 positive T-ALL.

KW - Autophagy

KW - NUP214-ABL1

KW - PI3K/Akt/mTOR signaling

KW - T-Acute Lymphoblastic Leukemia

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84999018313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999018313&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13035

DO - 10.18632/oncotarget.13035

M3 - Article

VL - 7

SP - 79842

EP - 79853

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 48

ER -